AOD-9604

TGA Approved (Australia, oral)

Also known as: Anti-Obesity Drug 9604

GLP-1 / Weight LossSubcutaneousOral

A modified fragment of human growth hormone (amino acids 177-191) that stimulates lipolysis without the growth-promoting or diabetogenic effects of full GH.

Molecular Weight1815.1 Da

Half-Life (t½)~6-8 hours

SequencehGH fragment 177-191 (modified)

Mechanism of Action

Mimics the lipolytic region of GH. Stimulates fat breakdown in adipose tissue, inhibits lipogenesis, and does not affect blood sugar or growth.

Dosing Protocol

250-500 mcg/day subcutaneous, on an empty stomach. Cycle 12 weeks on, 4 weeks off.

Open peptide calculator

Reconstitution

5mg vial + 2mL BAC water = 2500 mcg/mL.

Storage

Lyophilized: -20°C. Reconstituted: 2-8°C.

Side Effects

●Generally well-tolerated
●Mild injection site reactions
●Headache (rare)

Key Research Findings

●Reduced body fat without affecting IGF-1 levels
●TGA approval for osteoarthritis treatment (oral)
●No effect on blood glucose in clinical studies

Latest Verified Lab Report

No lab reports available for AOD-9604 yet.

Community-funded testing results will appear here.

Vendor Trust Leaderboard

For AOD-9604

Trust leaderboard coming soon.

Vendor rankings based on verified lab test results.

Active Deals

Gen Peptide

10% OFF

Shop Vendor